Omega 3

Phase 3Small molecule

MMassachusetts General Hospital

Omega 3 is one of 367 small molecule programs targeting Nicotine Dependence. It is currently in Phase 3.

Indications

Total Trials

Active Trials

366

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nicotine DependenceActive, not recruiting

PyelonephritisActive, not recruiting

TachycardiaActive, not recruiting

Brain InjuryActive, not recruiting

NecrosisActive, not recruiting

Oxidative StressActive, not recruiting

AnemiaActive, not recruiting

CataractActive, not recruiting

PeriodontitisActive, not recruiting

EpilepsyActive, not recruiting

Nicotine DependencePhase 3

Active, not recruiting

PyelonephritisPhase 3

Active, not recruiting

TachycardiaPreclinical

Active, not recruiting

Brain InjuryPreclinical

Active, not recruiting

NecrosisPhase 3

Active, not recruiting

Oxidative StressPhase 2/Phase 3

Active, not recruiting

AnemiaPhase 2/Phase 3

Active, not recruiting

CataractPreclinical

Active, not recruiting

PeriodontitisPreclinical

Active, not recruiting

EpilepsyPhase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Omega 3

MMassachusetts General Hospital

Phase 3

1 2

Calan

VVal Adams

Preclinical

4 3

Rituxan

Roche

Preclinical

—4

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Anticoagulants

Sanofi

Preclinical

2 7

Direct Anticoagulant

Bayer

Preclinical

1 8

Calcium

Eli Lilly

Preclinical

1 9

Warfarin Sodium

Boehringer Ingelheim

Preclinical

3 10

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Treatment Resistant Depression

NCT05774665

Clinical

Trials by Indication[1]

Dry Eye1 trial

A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye

Completed·TThe University of New South Wales·Phase 3·NCT02871440·40 enrolled

Pregnancy1 trial

The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction

Completed·—·Phase 2·NCT02696577·68 enrolled

Critically Ill Patients1 trial

Omega-3 Fatty Acid for Critically Ill Patients.

Completed·MMenoufia University·N/A·NCT03388450·110 enrolled

Efficacy1 trial

Efficacy of Fish Oil in Lupus Patients

Completed·—·Phase 4·NCT00828178·106 enrolled

Brain Injury1 trial

Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)

Withdrawn·DDeborah Yurgelun-Todd·N/A·NCT01515917

21 more indications

Tachycardia1 trial

Impact of Omega 3 in Treatment of Inappropriate Sinus Tachycardia

Completed·—·N/A·NCT07138131·60 enrolled

Anemia1 trial

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

Completed·—·Phase 2/3·NCT04301336·350 enrolled

Oxidative Stress1 trial

Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia

Completed·—·Phase 2/3·NCT04292314·350 enrolled

ART1 trial

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

Terminated·—·Phase 3·NCT00935766·76 enrolled

Necrosis1 trial

Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)

Completed·SShahid Beheshti University of Medical Sciences·Phase 3·NCT01521845·104 enrolled

Epilepsy1 trial

Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study

Unknown status·SSeoul National University Hospital·Phase 2·NCT02899741·30 enrolled

Pyelonephritis1 trial

Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children

Unknown status·SShahid Beheshti University·Phase 3·NCT02192580·60 enrolled

Periodontitis1 trial

Effects of Omega-3 as an Adjunct to Non-Surgical Periodontal Therapy on Chemerin Level in Periodontitis Patients With Diabetes: A Randomized Clinical Trial

Completed·—·N/A·NCT06463535·30 enrolled

Recurrent aphthous stomatitis1 trial

Omega-3 and Quality of Life in Recurrent Aphthous Stomatitis Patients

Unknown status·OOctober 6 University·Phase 2·NCT01831453·50 enrolled

Cardiovascular Risk Factor1 trial

Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins

Completed·—·N/A·NCT00976872·52 enrolled

Endothelial Function1 trial

Effect of Omega-3 Fatty Acid on Endothelial Function

Completed·NNordlandssykehuset HF·Phase 3·NCT01813006·34 enrolled

Cataract1 trial

Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery

Unknown status·SSamsung Medical Center·N/A·NCT04411615·30 enrolled

Atrial Fibrillation1 trial

Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation

Completed·MMontreal Heart Institute·Phase 3·NCT01235130·337 enrolled

Insulin Sensitivity1 trial

Omega-3 Fatty Acids and Insulin Sensitivity

Completed·MMayo Clinic·Phase 3·NCT01686568·31 enrolled

Adolescent1 trial

Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania

Completed·UUniversity of Cincinnati·Phase 2·NCT00917501·55 enrolled

Nicotine Dependence1 trial

Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence

Completed·FFederal University of São Paulo·Phase 3·NCT01735279·58 enrolled

Pediatric1 trial

Inositol and Omega-3 Fatty Acids in Pediatric Mania

Completed·MMassachusetts General Hospital·Phase 4·NCT01396486·69 enrolled

Percutaneous Coronary Intervention (PCI)1 trial

Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)?

Unknown status·SShiraz University of Medical Sciences·Phase 3·NCT01723345·90 enrolled

Ocular Surface Disease1 trial

Outcome of Omega 3 FA and Punctal Plugs on Ocular Surface Disease

Completed·—·Phase 4·NCT03686059·90 enrolled

Treatment Resistant Depression1 trial

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT05774665·14 enrolled

Unspecified1 trial

Effect of Omega 3 as an Immunomodulator Adjunct to Periodontal Debridement

Completed·—·N/A·NCT04389931·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Omega 3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omega 3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omega 3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMassachusetts General Hospital

Omega 3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Dry Eye1 trial

Pregnancy1 trial

Critically Ill Patients1 trial

Efficacy1 trial

Brain Injury1 trial

Tachycardia1 trial

Anemia1 trial

Oxidative Stress1 trial

ART1 trial

Necrosis1 trial

Epilepsy1 trial

Pyelonephritis1 trial

Periodontitis1 trial

Recurrent aphthous stomatitis1 trial

Cardiovascular Risk Factor1 trial

Endothelial Function1 trial

Cataract1 trial

Atrial Fibrillation1 trial

Insulin Sensitivity1 trial

Adolescent1 trial

Nicotine Dependence1 trial

Pediatric1 trial

Percutaneous Coronary Intervention (PCI)1 trial

Ocular Surface Disease1 trial

Treatment Resistant Depression1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News